Skip to NavigationSkip to content

transparancy

Servier slammed over UK trial transparency failure

servier image

Servier has been found guilty of the most serious breach of the UK’s pharma code of conduct after failing to publish full details of several trials for its depression drug Valdoxan.

An anonymous complainant used the ABPI’s recent study on trial data disclosure called ‘Current Medical Research & Opinion’, which was published late last year, to bring Servier to account.

Bad pharma, good pharma: an insider’s view

Published on 30/05/13 at 11:15am
Goldacre image

Most people in the pharmaceutical industry, particularly in the UK, will be well-acquainted with Ben Goldacre by now. 

He published his Bad Pharma book in September 2012, and since then has managed to attract (some might say court) huge media attention for his message, that “drug companies mislead doctors and harm patients”.

UCB warns of data ‘voyeurism’

UCB image

UCB chief executive Roch Doliveux has attacked the idea of making all clinical trial data publicly available, saying it could be ‘dangerous and misleading’.

“I support the notion of transparency,” said Doliveux. “I don’t support the notion of voyeurism. You have to put any data in context.”

UCB data is open to ‘credible’ researchers to look at, he went on, but warned against a free-for-all. “That’s the guiding principle: somebody who has the skills to make a decision,” he explained.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches